vs

Side-by-side financial comparison of SIERRA BANCORP (BSRR) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $39.3M, roughly 1.5× SIERRA BANCORP). SIERRA BANCORP runs the higher net margin — 40.4% vs -83.0%, a 123.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 3.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 2.6%).

Sierra Bancorp is a U.S.-based regional bank holding company operating the Bank of the Sierra brand. It offers full retail and commercial banking services including deposit products, consumer and commercial loans, and mortgages, primarily serving local communities, SMEs and individual customers across Central and Southern California.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

BSRR vs RYTM — Head-to-Head

Bigger by revenue
RYTM
RYTM
1.5× larger
RYTM
$57.3M
$39.3M
BSRR
Growing faster (revenue YoY)
RYTM
RYTM
+33.1% gap
RYTM
36.9%
3.8%
BSRR
Higher net margin
BSRR
BSRR
123.3% more per $
BSRR
40.4%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
2.6%
BSRR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BSRR
BSRR
RYTM
RYTM
Revenue
$39.3M
$57.3M
Net Profit
$12.9M
$-47.5M
Gross Margin
91.6%
Operating Margin
43.6%
-82.2%
Net Margin
40.4%
-83.0%
Revenue YoY
3.8%
36.9%
Net Profit YoY
24.4%
-9.6%
EPS (diluted)
$0.96
$-0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BSRR
BSRR
RYTM
RYTM
Q4 25
$39.3M
$57.3M
Q3 25
$40.0M
$51.3M
Q2 25
$39.2M
$48.5M
Q1 25
$36.8M
$32.7M
Q4 24
$37.9M
$41.8M
Q3 24
$38.6M
$33.3M
Q2 24
$37.8M
$29.1M
Q1 24
$37.3M
$26.0M
Net Profit
BSRR
BSRR
RYTM
RYTM
Q4 25
$12.9M
$-47.5M
Q3 25
$9.7M
$-52.9M
Q2 25
$10.6M
$-46.6M
Q1 25
$9.1M
$-49.5M
Q4 24
$10.4M
$-43.3M
Q3 24
$10.6M
$-43.6M
Q2 24
$10.3M
$-32.3M
Q1 24
$9.3M
$-141.4M
Gross Margin
BSRR
BSRR
RYTM
RYTM
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Q1 24
89.2%
Operating Margin
BSRR
BSRR
RYTM
RYTM
Q4 25
43.6%
-82.2%
Q3 25
31.7%
-102.6%
Q2 25
36.3%
-93.4%
Q1 25
33.4%
-143.7%
Q4 24
33.3%
-98.6%
Q3 24
37.4%
-132.0%
Q2 24
37.6%
-139.2%
Q1 24
33.9%
-538.7%
Net Margin
BSRR
BSRR
RYTM
RYTM
Q4 25
40.4%
-83.0%
Q3 25
24.2%
-103.1%
Q2 25
27.1%
-96.1%
Q1 25
24.8%
-151.4%
Q4 24
34.1%
-103.6%
Q3 24
27.5%
-131.2%
Q2 24
27.2%
-110.9%
Q1 24
25.0%
-544.4%
EPS (diluted)
BSRR
BSRR
RYTM
RYTM
Q4 25
$0.96
$-0.73
Q3 25
$0.72
$-0.82
Q2 25
$0.78
$-0.75
Q1 25
$0.65
$-0.81
Q4 24
$0.73
$-0.71
Q3 24
$0.74
$-0.73
Q2 24
$0.71
$-0.55
Q1 24
$0.64
$-2.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BSRR
BSRR
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$135.6M
$388.9M
Total DebtLower is stronger
$49.5M
Stockholders' EquityBook value
$364.9M
$139.1M
Total Assets
$3.8B
$480.2M
Debt / EquityLower = less leverage
0.14×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BSRR
BSRR
RYTM
RYTM
Q4 25
$135.6M
$388.9M
Q3 25
$95.5M
$416.1M
Q2 25
$130.0M
$291.0M
Q1 25
$159.7M
$314.5M
Q4 24
$100.7M
$320.6M
Q3 24
$132.8M
$298.4M
Q2 24
$184.0M
$319.1M
Q1 24
$119.2M
$201.2M
Total Debt
BSRR
BSRR
RYTM
RYTM
Q4 25
$49.5M
Q3 25
$49.5M
Q2 25
$49.4M
Q1 25
$49.4M
Q4 24
$49.4M
Q3 24
$49.4M
Q2 24
$49.3M
Q1 24
$49.3M
Stockholders' Equity
BSRR
BSRR
RYTM
RYTM
Q4 25
$364.9M
$139.1M
Q3 25
$360.1M
$148.8M
Q2 25
$355.7M
$-11.9M
Q1 25
$351.8M
$18.9M
Q4 24
$357.3M
$21.7M
Q3 24
$358.7M
$11.2M
Q2 24
$350.0M
$39.3M
Q1 24
$345.1M
$61.6M
Total Assets
BSRR
BSRR
RYTM
RYTM
Q4 25
$3.8B
$480.2M
Q3 25
$3.7B
$506.9M
Q2 25
$3.8B
$372.7M
Q1 25
$3.6B
$386.7M
Q4 24
$3.6B
$392.3M
Q3 24
$3.7B
$363.6M
Q2 24
$3.7B
$381.8M
Q1 24
$3.6B
$258.7M
Debt / Equity
BSRR
BSRR
RYTM
RYTM
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.14×
Q1 25
0.14×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.14×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BSRR
BSRR
RYTM
RYTM
Operating Cash FlowLast quarter
$33.7M
$-25.4M
Free Cash FlowOCF − Capex
$32.2M
FCF MarginFCF / Revenue
81.9%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
2.61×
TTM Free Cash FlowTrailing 4 quarters
$50.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BSRR
BSRR
RYTM
RYTM
Q4 25
$33.7M
$-25.4M
Q3 25
$14.9M
$-26.6M
Q2 25
$-35.9M
$-23.3M
Q1 25
$40.6M
$-40.4M
Q4 24
$57.2M
$-18.8M
Q3 24
$27.4M
$-25.2M
Q2 24
$620.0K
$-29.1M
Q1 24
$7.0M
$-40.7M
Free Cash Flow
BSRR
BSRR
RYTM
RYTM
Q4 25
$32.2M
Q3 25
$14.7M
Q2 25
$-36.3M
Q1 25
$40.2M
Q4 24
$56.0M
Q3 24
$27.3M
Q2 24
$202.0K
Q1 24
$6.6M
FCF Margin
BSRR
BSRR
RYTM
RYTM
Q4 25
81.9%
Q3 25
36.7%
Q2 25
-92.6%
Q1 25
109.5%
Q4 24
147.9%
Q3 24
70.7%
Q2 24
0.5%
Q1 24
17.7%
Capex Intensity
BSRR
BSRR
RYTM
RYTM
Q4 25
3.9%
Q3 25
0.6%
Q2 25
1.2%
Q1 25
1.0%
Q4 24
3.1%
Q3 24
0.3%
Q2 24
1.1%
Q1 24
1.0%
Cash Conversion
BSRR
BSRR
RYTM
RYTM
Q4 25
2.61×
Q3 25
1.54×
Q2 25
-3.37×
Q1 25
4.46×
Q4 24
5.51×
Q3 24
2.58×
Q2 24
0.06×
Q1 24
0.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons